Alector (ALEC)
NASDAQ:ALEC
ALEC Stock Chart & Stats
$2.12
-$0.09(-4.55%)
At close: 4:00 PM EST
$2.12
-$0.09(-4.55%)
Day’s Range― - ―
52-Week Range$0.87 - $3.40
Previous CloseN/A
Volume194.31K
Average Volume (3M)838.14K
Market Cap
$233.97M
Enterprise Value$191.16M
Total Cash (Recent Filing)$256.02M
Total Debt (Recent Filing)$36.23M
Price to Earnings (P/E)―
Beta2.08
Next Earnings
Apr 30, 2026EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding110,362,580
10 Day Avg. Volume661,467
30 Day Avg. Volume838,137
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)5.24
Price to Sales (P/S)7.63
P/FCF Ratio-0.87
Enterprise Value/Market Cap0.82
Enterprise Value/Revenue9.08
Enterprise Value/Gross Profit10.18
Enterprise Value/Ebitda-1.40
Forecast
1Y Price Target
$2.88Price Target Upside35.85% Upside
Rating ConsensusHold
Number of Analyst Covering7
EPS Forecast (FY)-0.85
Revenue Forecast (FY)$36.77M
Bulls Say, Bears Say
Bulls Say
Dosing And Safety ProfileTargeting a less‑exposed transferrin receptor epitope lowers hematological risk while the tau siRNA modality supports peripheral dosing, which may permit higher brain penetration with reduced monitoring and easier patient adoption.
Platform StrategyShift toward a proprietary brain carrier platform concentrates development on an anti‑amyloid antibody and a tau siRNA program, which could increase clarity and value if platform assets progress into clinical testing.
Therapeutic DifferentiationThe lead anti‑amyloid antibody's preserved effector function supports more efficient plaque clearance and differentiates the program from competitors, potentially strengthening clinical competitiveness.
Bears Say
Biological Translatability SkepticismRecent failures of similar PGRN‑targeting antibodies fuel skepticism about biological translatability, making investors cautious about related programs' prospects.
Clinical Readout RiskDependence on an interim futility readout for the Alzheimer's trial creates significant binary clinical risk that could trigger sharp market reactions if results are unfavorable.
Pipeline SetbacksDiscontinuation of a late‑stage therapy following trial failure erodes near‑term investor confidence and highlights execution and risk in the development pipeline.
Alector News
ALEC FAQ
What was Alector’s price range in the past 12 months?
Alector lowest stock price was $0.87 and its highest was $3.40 in the past 12 months.
What is Alector’s market cap?
Alector’s market cap is $233.97M.
When is Alector’s upcoming earnings report date?
Alector’s upcoming earnings report date is Apr 30, 2026 which is in 33 days.
How were Alector’s earnings last quarter?
Alector released its earnings results on Feb 25, 2026. The company reported -$0.34 earnings per share for the quarter, beating the consensus estimate of -$0.374 by $0.034.
Is Alector overvalued?
According to Wall Street analysts Alector’s price is currently Undervalued.
Does Alector pay dividends?
Alector does not currently pay dividends.
What is Alector’s EPS estimate?
Alector’s EPS estimate is -0.28.
How many shares outstanding does Alector have?
Alector has 110,362,580 shares outstanding.
What happened to Alector’s price movement after its last earnings report?
Alector reported an EPS of -$0.34 in its last earnings report, beating expectations of -$0.374. Following the earnings report the stock price went up 7.113%.
Which hedge fund is a major shareholder of Alector?
Currently, no hedge funds are holding shares in ALEC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alector Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.88 (35.85% Upside)
$2.88 (35.85% Upside)
Blogger Sentiment
Neutral
ALEC Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 124.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 7.3%
Last 30 Days ▼ 7.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
63.07%
12-Months-Change
Fundamentals
Return on Equity
-224.96%
Trailing 12-Months
Asset Growth
-37.38%
Trailing 12-Months
Company Description
Alector
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
ALEC Stock 12 Month Forecast
Average Price Target
$2.88
▲(35.85% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---